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AbstrAct
primary hepatic rhabdomyosarcoma is rare, making decisions regarding locoregional management with resection and/or 
conventional radiation difficult. We present a novel treatment approach for a pediatric patient diagnosed with rhabdomy-
osarcoma diffusely involving the liver. this patient underwent treatment with yttrium-90 (Y-90) microspheres followed by 
external beam radiation therapy (eBrt) to residual disease, interdigitated with systemic chemotherapy. Initial post-radiation 
imaging showed significant response to treatment, and she experienced minimal acute toxicities and no long-term toxicities. 
she developed recurrent pet-avid disease 23 months after Y-90 treatment, necessitating further local and continued systemic 
therapies. We report on the tumor control following Y-90 and eBrt treatment.
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Introduction
Rhabdomyosarcoma is a malignant soft tissue 
cancer that commonly manifests in the skeletal 
muscle, accounting for approximately 3% of malig-
nant tumors in children and associated with vari-
able overall survival based on risk stratification [1, 
2]. Typical management includes chemotherapy 
and surgical resection frequently followed by ra-
diation therapy; however, resection may not be fea-
sible in select cases [3]. One such location can be 
the liver. Although external beam radiation therapy 
(EBRT) is typically employed in unresectable cases, 
diffuse liver involvement presents a problem due 
to the risk of irreversible and even fatal radiation-
induced liver disease. Such cases, therefore, neces-
sitate the use of other local treatment strategies.
Selective internal radiation therapy (SIRT) with 
yttrium-90 (Y-90) is a minimally invasive procedure 
that takes advantage of the liver’s dual blood supply, 
in which hepatocytes are primarily supplied by the 
portal vein and tumor cells by the hepatic artery, 
to preferentially deliver beta-emitting Y-90 micro-
spheres to tumors [4]. This allows delivery of higher 
radiation doses to tumors while selectively sparing 
healthy hepatocytes and is frequently utilized to treat 
both primary and metastatic liver tumors in adults 
[5, 6]. SIR-Spheres, one type of Y-90 microsphere, 
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have been designed to be small enough to access 
tumor microvasculature but large enough to remain 
within the capillary bed to limit toxic effects [7]. 
Y-90 is generally well-tolerated with minimal side 
effects in adults, often limited to mild fatigue and 
abdominal discomfort [8]. However, there are very 
few reports of its tolerability and efficacy in pediatric 
patients. A case series published in 2018 of 10 chil-
dren and adolescents reported 4 patients developing 
fatigue and fevers without signs of infection, sug-
gesting it may be safe in pediatric patients [9].
Here, we present the case of a pediatric patient with 
rhabdomyosarcoma with diffuse liver involvement 
treated at our institution with bilobar SIR-Spheres 
followed by EBRT to residual disease. We present 
the safety and efficacy of her treatment course and 
its implications for Y-90 treatment in pediatric pa-
tients with diffuse liver involvement. We also de-
lineate dosimetric considerations when combining 
Y-90 and EBRT, a treatment approach which may be 
considered for similar cases in the future. 
case report
A 5-year-old female with no significant past 
medical history presented with 2 days of abdomi-
nal pain and anorexia and a palpably enlarged 
liver. MRI showed a large heterogeneous liver 
with innumerable confluent multiseptated lesions 
compatible with diffuse involvement, portal vein 
thrombosis, and grade 1 esophageal and gastric 
varices (Fig. 1A). Ultrasound-guided biopsy of the 
liver mass demonstrated embryonal rhabdomyo-
sarcoma, and PET/MRI showed disease diffusely 
involving the liver with potential tumor throm-
bus in the portal and superior mesenteric veins. 
She was started on induction chemotherapy with 
vincristine, dactinomycin, and cyclophosphamide 
alternating with vincristine and irinotecan/topote-
can for 9 months, during which she developed ex-
pected side effects including fever, vomiting, weight 
loss, and abdominal pain. Follow-up MRI showed 
persistent hepatomegaly with slight decrease in the 
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Figure 1. axial abdominal MrI images throughout treatment course. A. MrI on day of diagnosis showing heterogeneous 
hepatomegaly compatible with diffuse tumor involvement; portal vein thrombosis also present. b. MrI after initial 
chemotherapy regimen demonstrating persistent hepatomegaly with mild improvement of intrahepatic disease burden; 
residual mild enhancement in portal vein, proximal mesenteric vein, and splenic vein. c. MrI 14 weeks after Y-90 treatment 
showing mixed response of intrahepatic tumor and extensive tumor growth within the portal venous system with distension 
of superior mesenteric vein and splenic vein. D. MrI prior to salvage eBrt showing mixed response to salvage chemotherapy 
with areas of tumor progression in liver segments 5 and 8 and the splenoportal system
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extent of intrahepatic disease (e.g., conglomerate 
right lobe lesions measured 5.6 × 5.3 cm from 6.5 
× 6.7 cm) and a mild enhancement of surrounding 
veins (Fig. 1B). 
However, due to persistent diffuse liver involve-
ment, neither surgical resection nor EBRT was 
considered feasible, and Y-90 microspheres were 
suggested as a non-standard treatment option. 
Mapping angiogram (Fig. 2) demonstrated exten-
sive tumor throughout both hepatic lobes. The lung 
shunt was acceptable at 6.2% (radiation pneumoni-
tis may be seen with lung shunts > 20%). Protective 
coil embolism of an accessory splenic artery aris-
ing from the gastrohepatic trunk was performed 
to prevent SIR-Spheres flowing through this vessel 
and potentially damaging healthy tissue. The body 
surface area method was used to calculate the dose 
of SIR-Spheres [10]. She initially received 18.8 mCi 
to the right lobe without complication. Four weeks 
later, she received 3.9 mCi to the left lobe, at which 
point stasis was noted as there was no antegrade 
blood flow seen on angiography preventing deliv-
ery of the entire calculated activity of microspheres. 
MRI 14 weeks later showed mixed response within 
the liver with extensive tumor growth in unirradiat-
ed portal venous branches causing distension of the 
superior mesenteric vein and splenic vein (Fig. 1C). 
She began salvage chemotherapy with vincris-
tine, cyclophosphamide, and temsirolimus; how-
ever, due to poor tolerability, this regimen was dis-
continued. Follow-up MRI 8 weeks after initiating 
salvage chemotherapy showed areas of decreased 
tumor bulk, likely reflecting treatment response, 
but multiple other areas of tumor progression, par-
ticularly within segments 5 and 8 and the spleno-
portal system (Fig. 1D). 
Due to this progression, she was considered for 
EBRT which had been reported to be safe after Y-90 
in adults [11]. Decision was made to proceed with 
definitive EBRT to all known disease, including 42 
Gy in 14 fractions to the extrahepatic disease and 
a dose-reduction to 30 Gy in 10 fractions to the 
intrahepatic tumor due to the prior Y-90 treatment 
(Fig. 3). Table 1 includes dose constraints used for 
this EBRT treatment, which was well tolerated with 
only mild abdominal pain. Review of liver function 
tests (LFTs) showed no grade 2 or higher adverse 
events according to Common Terminology Criteria 
for Adverse Events version 5 after either radiation 
course [12]. Please see Table 2 for the evolution of 
the LFTs from diagnosis to post-EBRT.
After completing EBRT, she continued chemo-
therapy with vincristine, epirubicin, and carbo-
platin alternating with ifosfamide, etoposide, and 
vincristine for a total of 9 cycles over 11 months, 
during which she required multiple prolonged hos-
Figure 3. external beam radiation therapy plan showing 
intrahepatic volume treated with 30 Gy in 10 fractions and 
extrahepatic volume treated to 42 Gy in 14 fractions
Figure 2. Yttrium-90 mapping angiogram demonstrating 
extensive tumor involvement throughout both hepatic 
lobes with lung shunt 6.2%
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pitalizations (e.g., sepsis, rectal bleeding, and Clos-
tridium difficile infection). Follow-up PET/CT 6 
months after EBRT showed complete resolution of 
PET activity with persistent non-avid mass in por-
tal, splenic, and superior mesenteric veins. How-
ever, on imaging 15 months after salvage EBRT, she 
was found to have recurrence within the irradiated 
liver and portal vein and marginally irradiated ret-
roperitoneum. Due to prior Y-90 and EBRT to the 
liver, she underwent microwave ablation of the liver 
lesion with transient elevation of liver enzymes. She 
also received stereotactic body radiation therapy 
to the portal vein and retroperitoneal recurrences 
to 25 Gy in 5 fractions without acute or subacute 
toxicity. She subsequently developed further pro-
gression intrahepatically and in the portal vein, 
requiring biliary stent placement. She ultimately 
died from ascending cholangitis from multi-drug 
resistant Enterobacter cloacae 29 months after her 
Y-90 treatment.
Discussion
Local therapy for rhabdomyosarcoma is pri-
marily dictated by tumor location and underlying 
histology. However, in patients with diffuse liver 
involvement, both surgery and EBRT may be un-
feasible, necessitating the use of novel therapies.  
Treatment with Y-90 can be used to safely deliver 
higher radiation doses to liver tumors than EBRT 
[13]. While studies have shown improved survival 
rates in adults treated with Y-90 [14–16], such stud-
ies in pediatric patients are very few. Hawkins et 
al. (2013) reported two children with hepatocel-
lular carcinoma treated with Y-90 who survived 4 
months and 20 months post-treatment [17]. Agua-
do et al. (2018) reported the treatment of 10 pediat-
ric patients with primary hepatic malignancies with 
Y-90 with survival ranging from 2–20 months and 3 
patients tolerating re-treatment with Y-90 [9]. Our 
patient survived 26 months following Y-90 treat-
ment (and 41 months after diagnosis) with minimal 
toxicity from her local therapies, despite further 
EBRT and microwave ablation to the liver.
The selection of local therapy for rhabdomyosar-
coma involving the liver is further complicated by 
the known potential hepatotoxicity of several of the 
agents used in the treatment of rhabdomyosarcoma 
[18]. For example, veno-occlusive disease is consid-
ered a common side effect of cyclophosphamide, 
table 2. evolution of liver function tests from time of diagnosis to post-eBrt treatment 
Measurement Diagnosis Prior to Y-90 After Y-90 Prior to EBRT After EBRT
INr 1.3 1.2 1.3 – –
ptt 35.4 59.5* 44.4 – –
Bilirubin, total 1.7 0.4 0.4 0.7 1.3
Bilirubin, direct 1.1 < 0.2 < 0.2 0.3 0.6
aLt 144 56 60 81 102
ast 145 49 70 82 68
aLp 527 158 – – 360
protein, total 5.9 7.2 – – 5.9
albumin 3.3 4.6 – – 3.3
*indicates grade ≥ 2 severity as per ctcae version 5.0; eBrt — external beam radiation therapy; INr — international normalized ratio (normal range: 0.8–1.2); 
ptt — partial thromboplastin time in seconds (normal range: 22.2–36.0); total bilirubin in mg/dL (normal range: 0.0–1.2); direct bilirubin in mg/dL (normal 
range: 0.0–0.3); aLt — alanine aminotransferase in IU/L (normal range: 0–33); ast — aspartate aminotransferase in IU/L (normal range: 0–32); aLp — alkaline 
phosphatase in IU/L (normal range: 39–390); total protein in g/dL (normal range: 6.4–8.3); albumin in g/dL (normal range: 3.5–4.8)
table 1. Dose constraints used for external beam radiation 
therapy (eBrt) treatment. Liver dose constraints adopted 
from [11]. Kidney and spinal cord constraints were 
department standard dose constraints, as adopted from 
QUaNtec [19] 
Organs at risk Dose (Gy) or dose/volume parameters
Liver
Mean dose ≤ 2000 cGy
V500 cGy ≤ 86%
V1000 cGy ≤ 68%
V2000 cGy ≤ 49%
V3000 cGy ≤ 28%
V4000 cGy ≤ 20%
Kidneys (each) Mean dose ≤ 1800 cGy
V2000 cGy ≤ 32%
spinal cord Max dose ≤ 4500 cGy
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resulting in toxicity in 38% of patients who receive it 
in conjunction with total body irradiation. Similarly, 
other forms of hepatotoxicity including hepatitis, 
cholestasis, and steatosis are known to occur follow-
ing administration of vincristine, actinomycin-D, 
irinotecan, topotecan, ifosfamide, and etoposide — 
all of which she received at some point during the 
treatment of her rhabdomyosarcoma. Further, some 
of these side effects may be potentiated by radiation 
therapy. Despite this, she only experienced a grade 
2 prolongation of her PTT from her chemotherapy 
regimens and did not demonstrate any other grade 
2 or higher side effects following administration of 
Y-90, EBRT, or salvage chemotherapy regimens.
Here, we present a case of rhabdomyosarcoma 
diffusely involving the liver where no standard 
therapies were feasible. Y-90 followed by EBRT was 
well tolerated with minimal toxicity in our case. As 
rhabdomyosarcoma diffusely involving the liver is 
rare, trials establishing a standard of care for such 
patients are not feasible. However, prospective stud-
ies evaluating the safety and efficacy of Y-90 alone 
or followed by EBRT to residual disease in children 
with unresectable liver tumors may be possible. 
Treatment with Y-90 followed by salvage EBRT, as 
demonstrated in this case report, can be delivered 
both safely and effectively in children.
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